Article info

Download PDFPDF

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Authors

  1. Correspondence to Dr James Cheng-Chung Wei, Department of Internal Medicine, Institute of Medicine, Chung Shan Medical University, Chung Shan Medical University Hospital, Taichung 402, Taiwan; wei3228{at}gmail.com
View Full Text

Citation

Baeten D, Østergaard M, Wei JC, et al
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Publication history

  • Received February 28, 2018
  • Revised May 11, 2018
  • Accepted May 14, 2018
  • First published June 26, 2018.
Online issue publication 
August 10, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.